Product
TQB3616
Aliases
TQB3616 capsule
Name
TQB3616
4 clinical trials
4 indications
Indication
Hormone receptor positiveIndication
Breast NeoplasmsIndication
Breast CancerIndication
Advanced MalignanciesClinical trial
A Randomized, Double-blind, Parallel-controlled Phase III Trial Evaluating the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated HR-positive, HER2-negative Advanced Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of TQB2930 for Injection Monotherapy or in Combination for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Recurrent / Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Randomized, Double-blind, Parallel-controlled Phase III Trial to Evaluate the Efficacy and Safety of TQB3616 Combined With Endocrine Therapy Versus Placebo Combined With Endocrine Therapy in Hormone Receptors (HR)-Positive and Human Epidermal GrowthFactor Receptor-2 (HER2) -Negative Breast Cancer Adjuvant TherapyStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Clinical Study on Material Balance of [14C]TQB3616 in Healthy Chinese SubjectsStatus: Not yet recruiting, Estimated PCD: 2024-06-01